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Inefficient gene delivery is a critical factor limiting the 
use of nonviral methods in therapeutic applications 
including gene therapy and tissue engineering. There 
have been few efforts to understand or engineer the 
molecular signaling pathways that dictate the efficacy 
of gene transfer. Microarray analysis was used to deter-
mine endogenous gene expression profiles modulated 
during nonviral gene transfer. Nonviral DNA lipoplexes 
were delivered to HEK 293T cells. Flow cytometry was 
used to isolate a population of transfected cells. Expres-
sion patterns were compared between transfected and 
nontransfected samples, which revealed three genes 
that were significantly upregulated in transfected cells, 
including RAP1A, a GTPase implicated in integrin-medi-
ated cell adhesion, and HSP70B′, a stress-inducible gene 
that may be important for maintaining cell viability. 
Furthermore, RAP1A was also significantly upregulated 
in untransfected cells that were exposed to lipoplexes 
but that had not expressed the transgene as compared 
to control, untreated cells. Transfection in the presence 
of activators of upregulated genes was enhanced, dem-
onstrating the principle of altering endogenous gene 
expression profiles to enhance transfection. With a 
greater understanding of signaling pathways involved in 
gene delivery, more efficient nonviral delivery schemes 
capitalizing on endogenous factors can be developed to 
advance therapeutic applications.
Received 9 February 2011; accepted 9 May 2011; published online  
9 August 2011. doi:10.1038/mt.2011.161
IntroductIon
Gene delivery approaches provide a mechanism to directly alter 
gene expression within a cell population, with tremendous poten-
tial in basic science (e.g., to study gene expression), therapeutics 
(e.g., gene therapy to correct genetic deficiencies or treat acquired 
disease), and tissue engineering (e.g., to present factors in scaf-
folds that guide tissue formation). Nonviral delivery techniques 
are less efficient than viral systems, but offer the advantages of 
low toxicity and immunogenicity, lack of pathogenicity, and ease 
of production with greater control and flexibility, making these 
vectors attractive alternatives to viruses. Typical nonviral gene 
delivery systems involve the ionic/electrostatic complexation of 
DNA with cationic polymers (polyplexes)1 or lipids (lipoplexes).2 
Complexation protects DNA against degradation by nucleases and 
serum components and enhances cellular uptake by reducing the 
effective size of DNA and promoting interactions between posi-
tively charged DNA complexes and the negatively charged cellular 
membrane. These complexation agents also can facilitate intracel-
lular trafficking, while dissociating from the DNA to allow expres-
sion.3,4 However, even with complexation strategies as described 
above, both extracellular5 and intracellular6 barriers exist that pre-
vent efficient nonviral gene transfer. Extracellular barriers to gene 
delivery include mass transport limitations, cytotoxicity, degrada-
tion, and aggregation,5 as well as cell targeting. Once a complex 
reaches a target cell, intracellular barriers to gene transfer include 
cell binding, cell entry, release from endosomal compartments, 
cytosolic transit, nuclear entry,7 and subsequently expression of 
the transgene.6
To date, most efforts to understand and improve the efficiency 
of nonviral gene delivery have focused on altering the physico-
chemical properties of delivery systems and developing new deliv-
ery strategies, focusing on the physical and chemical characteristics 
of the cationic vector8–10 or examining the effect of complexing 
agents on subcellular localization/distribution,11 intracellular traf-
ficking and pharmacokinetics,12–14 and transfection efficiency of 
DNA complexes, providing only a fragmented understanding of 
that process because of the differences in techniques and study 
variables, without regard to the underlying cellular states or sig-
naling pathways. Even with these efforts, nonviral gene delivery 
remains inefficient and its mechanisms largely unknown because 
of the complexity of the process. The lack of direct information 
on the endogenous gene expression profiles and intracellular sig-
naling pathways that might be controlling transfection efficiency 
limits the optimal design of delivery vectors.
Microarray analysis has been performed to investigate the toxi-
cogenomics of nonviral vectors used for gene delivery.15–18 However 
in these previous studies, the objective was to treat the cells with 
cationic polymer or lipid (often in the absence of complexation 
with DNA) to observe the associated gene expression profiles and 
cellular responses, in particular cytotoxicity. In these studies, there 
was no isolation of transfected cells from untransfected, rather cell 
populations treated with vector alone or vector complexed with 
DNA were compared to untreated conditions. In most studies, 
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apoptosis was observed and confirmed with gene expression pro-
files, which should not be unexpected as nonviral vectors are typi-
cally more toxic when not complexed with DNA.19
While these previous studies have used microarray analysis 
to explore global gene expression profiles for pharmacological 
and toxicological studies of lipids and polymers used in nonvi-
ral gene delivery, there have been few efforts to understand the 
molecular signaling pathways that dictate efficient gene transfer. 
In this report, gene expression profiles of an isolated population of 
successfully transfected cells were investigated using microarray 
analysis and related to cellular mechanisms that might be respon-
sible for successful gene transfer. Upregulation of two identified 
genes was confirmed with transfection studies performed in the 
presence and absence of activators of these genes. With a greater 
understanding of key signaling pathways involved in gene deliv-
ery afforded by the analysis reported here, the mechanisms that 
render cells responsive to DNA transfer will be determined, which 
can be used to develop more efficient nonviral delivery schemes.
results
Microarray analysis was used to identify how endogenous gene 
expression profiles are modulated during nonviral gene transfer. 
Nonviral DNA complexes (composed of cationic lipids complexed 
with plasmid DNA encoding for green fluorescent protein, GFP) 
were delivered to HEK 293T human embryonic kidney epithelial 
cells, a widely used cell line in transfection experiments (Figure 1). 
Transfection conditions were optimized for both high transfec-
tion efficiency and low cytotoxicity (Supplementary Figure S1). 
Flow cytometry was then used to sort GFP+ cells from GFP− 
cells, allowing isolation of a population of transfected cells and a 
population of cells that had been exposed to complexes, but not 
transfected, respectively (Figure 1 and Supplementary Figure 
S2). Expression patterns were compared between GFP+ and GFP− 
samples (six versus three replicates), which revealed three genes 
that were statistically differentially expressed between the two 
samples (twofold or greater change in expression, false discovery 
rate (FDR) adjusted P < 0.05, Table 1). These three genes that were 
substantially upregulated in the GFP+ (transfected cells) as com-
pared to GFP− (untransfected cells), include RAP1A, a GTPase 
implicated in a variety of cell behaviors including integrin-medi-
ated cell adhesion; HSP70B′, a stress-inducible gene that encodes 
for a heat shock protein that may be important for maintaining 
cell viability; and PVT1, a non-protein coding oncogene.
Expression patterns were compared between GFP− and 
Control samples (three versus six replicates) to determine genes 
which may be upregulated in cells that have been exposed to DNA 
complexes, but that were not expressing GFP at the time when 
cells were sorted and RNA was isolated. RAP1A was the only gene 
to be upregulated, with a substantial fold change in expression 
(FDR adjusted P < 0.05, Table 2).
Finally, expression patterns were compared between GFP+ 
and Control samples (six replicates each), which revealed 19 genes 
Plasmid DNA
(pCMV-LUC/GFP)
Cationic lipid
(Lipofectamine 2000)
DNA complex
(DNA:lipid ratio of 1:1.5)
HEK 293T cells
Transfection assayed at
24 hours and GFP+ cells
sorted with flow cytometry
GFP−GFP+ Control
RNA extraction
Microarray analysis: Affymetrix GeneChip Human Genome U133 Plus 2.0
arrays analyzed via Affymetrix GeneChip Operating Software (GCOS)
Figure 1 schematic of experimental design. Cell transfection, sorting of transfected cells (GFP+) from untransfected cells (GFP−) cells using flow 
cytometry, as well as Control cell population, RNA extraction and microarray analysis used to generate gene expression profiles.
table 1 Genes upregulated in transfected cells (GFP+) as compared to untransfected cells (GFP−)
representative public Id Gene symbol Gene title Fold change
NM_002155/X51757 HSPA6 Heat shock 70 kd protein 6 (HSP70B′) 10.332/2.966a
AB051846 RAP1A RAP1A, member of RAS oncogene family 9.172
BG200951 PVT1 Pvt1 oncogene (non-protein coding) 2.507
Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.
aTwo fold changes are reported as this gene is located at two distinct probes on microarray.
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that were statistically differentially expressed between the two 
samples (twofold or greater change in expression, FDR adjusted 
P < 0.05, Table 3), including the three genes identified as upregu-
lated between GFP+ and GFP− (RAP1A, HSP70B′, and PVT1), as 
expected. In addition to RAP1A, there were other genes upreg-
ulated in GFP+ cells with a link to integrin activation and cell 
adhesion (Table 3), including two members of the solute carrier 
family of proteins, solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2 (LOC442497/SLC3A2/
CD98) and solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 (SLC1A4). In addition to upregulation 
of HSP70B′, the DnaJ (Hsp40) homolog, subfamily B, member 1 
gene was also shown to be upregulated in GFP+ cells as compared 
to Control cells (Table 3), and like HSP70B′, Hsp40 plays a role in 
a variety of cell functions related to cell stress. Other upregulated 
genes of interest include several potentially involved in apoptosis, 
including the activating transcription factor 3 (ATF3), a transcrip-
tion factor that may activate or repress transcription to allow cells 
to adapt to various responses, including apoptosis; the damage-
specific DNA binding protein 2 (DDB2), which facilitates the 
cellular response to DNA damage; the phosphoprotein enriched 
in astrocytes 15 gene (PEA15), which is a death effector domain-
containing protein, and thus could be implicated in apoptosis; 
and the protein phosphatase 1, regulatory (inhibitor) subunit 15A 
gene (PPP1R15A), which is a member of a group of genes whose 
transcript levels are increased following stressful growth arrest 
conditions and treatment with DNA-damaging agents. The actin, 
α-2 (ACTA2) gene, a component of the cytoskeleton, was also 
upregulated.
As RAP1A and HSP70B′ were both approximately tenfold 
upregulated in GFP+ cells as compared to GFP− cells, as well as 
substantially upregulated in GFP+ cells as compared to Control 
cells (and RAP1A was also upregulated in GFP− as compared 
to Control cells) their upregulation was confirmed by quantita-
tive real-time PCR, probing for expression of both RAP1A and 
HSP70B′ in GFP+, GFP−, and Control cells (Figure 2). These two 
genes were also further studied in transfection experiments, in the 
presence and absence of pharmacological activators of these two 
table 2 Genes upregulated in untransfected cells (GFP−) as compared to control cells
representative public Id Gene symbol Gene title Fold change
AB051846 RAP1A RAP1A, member of RAS oncogene family 59.162
AB051846 RAP1A RAP1A, member of RAS oncogene family 110.187
Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.
table 3 Genes upregulated in transfected cells (GFP+) as compared to control cells
representative public Id Gene symbol Gene title Fold change
AB051846 RAP1A RAP1A, member of RAS oncogene Family  542.631
AB051846 RAP1A RAP1A, member of RAS oncogene family 1016.865
NM_002155/X51757 HSPA6 Heat shock 70 kd protein 6 (HSP70B′) 12.001/3.773a
X65232/AA284829 ZNF79 Zinc finger protein 79 2.261/3.026a
NM_001674/AB066566 ATF3 Activating transcription factor 3 3.775/3.328a
NM_002394 SLC3A2 Solute carrier family 3 (activators of dibasic and neutral amino  
acid transport), member 2
2.121
BG538800 ZNF473 Zinc finger protein 473 2.004
BG200951 PVT1 Pvt1 oncogene (non-protein coding) 2.514
BE788667 PRR14 Proline rich 14 2.772
BC000487/NM_012230 POMZP3 /// ZP3 POM (POM121 homolog, rat) and ZP3 fusion /// zona pellucida  
glycoprotein 3 (sperm receptor)
2.532/2.664a
NM_000107 DDB2 Damage-specific DNA binding protein 2, 48 kd 2.521
NM_006145/BG537255 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 2.2/2.293a
BC002426 PEA15 Phosphoprotein enriched in astrocytes 15 2.047
AF003934 GDF15 /// LOC100292463 Growth differentiation factor 15 /// similar to growth  
differentiation factor 15
2.576
U83981/NM_014330 PPP1R15A Protein phosphatase 1, regulatory (inhibitor) subunit 15A 2.003/2.291a
NM_002133 HMOX1 Heme oxygenase (decycling)1 3.179
NM_001613 ACTA2 Actin, α-2, smooth muscle, aorta 2.116
AW592227 KHDRBS1 KH domain containing, RNA binding, signal transduction associated 1 2.015
BF340083 SLC1A4 Solute carrier family 1(glutamate/neutral amino acid transporter), member 4 2.554
Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.
aTwo fold changes are reported as this gene is located at two distinct probes on microarray.
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genes to determine if their modulation prior to DNA complex deliv-
ery might affect transfection efficiency. These transfection studies 
were performed in HEK 293T cells and NIH/3T3 mouse fibroblast 
cells. The fibroblast cells were used to determine if the genes iden-
tified as upregulated in HEK 293T cells might be global regula-
tors of gene transfer (i.e., affect transfection profiles in another 
cell type). For either cell type, cells were seeded, treatments were 
applied for a period of time, and then media was removed and 
replaced with fresh media containing DNA-lipid complexes. For 
RAP1A, 8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′-
cyclic monophosphate sodium salt (8CPT-2Me-cAMP, referred to 
as CPT), a cAMP analog that has been shown to specifically acti-
vate EPAC in a variety of cell lines, including HEK 293 cells, was 
added.20 EPAC is a cAMP-activated guanine-nucleotide exchange 
factor and thus regulator of RAP1A.20 For HSP70B′, the gene was 
activated by placing cells at 42.5 °C for 1 hour and allowing them 
to recover at 37 °C for 6 hours,21 a technique which has been shown 
to upregulate HSP70B′ expression levels in human epithelial cell 
lines. Standard transfection in the presence of vehicle alone was 
used as a control. Activation of RAP1A and HSP70B′ in both HEK 
293T and NIH/3T3 cells (Figures 3 and 4) resulted in approxi-
mately twofold enhancement of transfection.
dIscussIon
Recently, the fields of “toxicogenomics” and “polymer genom-
ics” have begun to investigate pharmacogenomic responses to 
synthetic polymers and nanomaterials used to deliver genes or 
drugs into cells, with a focus on cell toxicity and associated gene 
expression changes that control the cellular response to various 
drugs and genes.22 Most studies utilize gene expression profiles 
obtained by microarray technology, which allows for the accu-
rate representation of the cellular response to delivery vectors.18 
For instance, treatment of human A431 epithelial cells with cat-
ionic lipids altered expression of 27 genes involved in cell prolif-
eration, differentiation, and apoptosis,15 confirmed by apoptosis 
assays. However, in that study cells were merely treated with the 
cationic lipid without complexation first with DNA, and thus the 
results correlate to properties of the vector itself, and not transfec-
tion. Transcriptional effects of lipid-mediated transfection were 
explored in MCF-7 cells, and gene expression profiling revealed 
that the transfection reagents caused off-target effects and these 
effects were not attributed to expression of the transgene itself, but 
like in most reported studies, transfected cells were not isolated 
prior to RNA extraction for analysis.23 However, several genes and 
gene families identified in that study correlate with genes shown to 
be differentially expressed in this current study, identified between 
GFP+ and control samples (Table 3), including ATF3, HMOX1, 
PPP1R15A, and DNAJB1, as well as members of the heat shock 
family of proteins and the solute carrier gene family. Cationic 
polymers have also been examined for their toxicogenomic effect 
on cells, including polyethylenimine16 and dendrimers.17 In these 
studies, there was no isolation of transfected cells from untrans-
fected, rather just treated versus untreated using polymer alone 
or polymers complexed with DNA. Gene expression changed 
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Figure 2 Verification of gene expression profiles. Real-time PCR was 
performed to verify microarray results for (a) RAP1A and (b) HSP70B′. 
Data normalized to 18S endogenous control and reported as mean with 
SEM.
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Figure 3 RAP1A activation and dnA delivery. Transfection in (a) HEK 
293T and (b) NIH/3T3 cells in with activator of Rap1a (CPT), compared 
to standard transfection conditions with vehicle. Transfection is reported 
as relative light units (RLU) per protein amount, represented as mean 
with SEM. Number in parentheses represents fold changes over standard 
transfection.
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in ~10% of the genes16 and cationic-dendrimer–induced gene 
changes in cells were increased upon complexation with small 
interfering RNA molecules,17 suggesting the presence of the den-
drimer might help determine the level of gene silencing by small 
interfering RNAs. Microarray analysis was also used to study local 
tissue response after delivery of a polymeric gene delivery system 
in vivo.18 Specifically, the toxicological profile of polyethylen-
imine, chitosan, and their complexes with DNA was determined 
in the mouse lung after administration of these complexes. Genes 
involved in stress reactions were induced by polyethylenimine, 
but also genes that stabilized the reporter protein luciferase and 
other proteins, but again, profiles were not determined on pure 
populations of transfected cells. These previous studies highlight 
not only the importance of understanding cellular responses to 
gene delivery agents, but also the importance of studying an iso-
lated population of transfected cells to identify genes that may be 
responsible for successful gene transfer.
upregulation of genes involved in integrin  
activation and cell adhesion
In this current study, gene expression profiles of successfully 
transfected cells provide molecular evidence for some findings 
in the literature on nonviral delivery mechanisms, including the 
role of integrin activation and cell adhesion. The RAP1A gene was 
determined to be upregulated in transfected cells (GFP+) as com-
pared to untransfected cells (GFP−) (Table 1), as well as upregu-
lated in untransfected cells (GFP−) as compared to control cells 
(Table 2), and highly upregulated in transfected cells (GFP+) as 
compared to control cells (Table 3). As stated above, RAP1A is a 
Ras-like GTPase implicated in growth modulation, differentiation, 
and integrin-mediated cell adhesion.24 RAP1A-mediated adhe-
sion and spreading has been demonstrated in several cell types, 
including fibroblasts25 and endothelial cells.26 RAP1A appears 
to modulate cell adhesion and spreading through the Rho fam-
ily of GTPases, with RAC1 required downstream of RAP1A for 
cell spreading. Overexpression of RAP1A has been shown to acti-
vate integrins and inhibition of RAP1A inhibits integrins,27 which 
has been shown to block cell adhesion to various substrates. The 
overexpression of RAP1A in GFP+ cells indicates that it may play 
a role in nonviral gene delivery; furthermore its upregulation in 
GFP− cells suggests that RAP1A expression may also be important 
for internalization of DNA complexes.
In addition to RAP1A, there were other genes upregulated 
in transfected cells (GFP+) as compared to Control cells with a 
link to integrin activation and cell adhesion (Table 3), including 
LOC442497/SLC3A2/CD98 and SLC1A4. In particular, SLC3A2 
(CD98) is a type II membrane glycoprotein expressed in all cell 
types, with the exception of platelets, and is a major contributor 
to the integrin-dependent activation of RAC.28 CD98 has been 
shown to promote activity of α5β1 integrin in fibroblast cultures 
and cells deficient in this gene are markedly defective in integrin-
dependent cell spreading and migration.29
The upregulation of genes involved in integrin activation and 
cell adhesion explain studies that link the presence of extra cellular 
matrix molecules to nonviral gene transfer. The addition of fibronec-
tin to lipoplexes, for example, enhanced transfection efficiency in 
prostate tumor cells,30 most likely by exposing the integrin binding 
site in fibronectin available upon fibronectin binding to lipoplexes, 
and thus enhancing the association of the DNA complexes with the 
cells. Fibronectin or collagen I addition to DNA calcium phosphate 
particles resulted in high transgene expression in mammalian 
cells, presumably since these particles could be recognized by the 
integrin receptors for subsequent internalization.31 Extracellular 
matrix molecules have also been shown to enhance transfection 
in substrate-mediated gene delivery strategies,32–35 where plasmid 
DNA or DNA complexes are immobilized to a surface or biomate-
rial that supports cell adhesion, thereby placing the DNA directly 
in the cellular microenvironment,36 most likely by promoting cell 
adhesion and the DNA polyplex internalization process.
upregulation of genes involved in stress  
response (heat shock)
The heat shock 70 kd protein 6 gene (HSPA6) was found to be 
upregulated in transfected cells (GFP+) as compared to untrans-
fected cells (GFP−) (Table 1). The heat shock protein 70 family is 
a group of chaperones involved in protein folding, stabilization, 
and shuttling functions through the cell. Members of this family 
can be induced by various cellular stresses.37 HSP70B′, a member 
of the family, is strictly inducible, having no detectable levels of 
expression in most cells,38 and may be important for maintaining 
cell viability37 and cytoprotection.21 In addition, the DnaJ (Hsp40) 
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Figure 4 HsP70B′ activation and dnA delivery. Transfection in 
(a) HEK 293T and (b) NIH/3T3 cells that were heat-shocked compared 
to standard transfection conditions. Transfection is reported as relative 
light units (RLUs) per protein amount, represented as mean with SEM. 
Number in parentheses represents fold changes over standard transfec-
tion. (**P <0.01).
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homolog, subfamily B, member 1 gene was also shown to be 
upregulated in transfected cells (GFP+) as compared to Control 
cells (Table 3), and like HSP70B′, plays a role in a variety of cell 
functions and has been shown to enhance nuclear localization of 
viral particles.39
The upregulation of genes involved in stress response indicate 
that a cell’s ability to respond to stress could control transfection 
efficiency. Thus, expression of the HSP70B′ gene may be impor-
tant for maintaining cell viability37 during transfection. A related 
member of the family, hsp70, was also shown to be upregulated in 
human A431 epithelial cells in response to treatment with cationic 
lipids.15 In addition to protecting the cells from the stress of treat-
ment with DNA complexes, HSP70B′ and DnaJ have also been 
shown to be involved in nuclear import of viral particles39,40 and 
thus could potentially be involved with nuclear entry of nonviral 
gene delivery complexes, in particular those with plasmids con-
taining viral promoters, thereby improving transfection levels.
upregulation of genes involved in apoptosis
Several genes with potential roles in apoptosis were found to be 
upregulated in transfected cells (GFP+) as compared to Control 
cells (Table 3), including the activating transcription factor 3 
(ATF3) gene. ATF3 induction may activate or repress transcrip-
tion to allow cells to adapt to various stresses and stimuli, includ-
ing induction of apoptosis.41 Typically expressed in low levels, 
ATF3 is a stress-inducible gene.42 While ATF3 has been shown to 
be a key regulator in cell stress response, whether its expression 
is a protective response or if it is part of the cellular response that 
leads to detrimental outcomes seems to be dependent on the cell 
type and nature of the stimulus. These dual roles have now led to 
the characterization of ATF3 as an “adaptive response” gene that 
participates in cellular processes to adapt to extra- or intracellular 
changes.41 In addition to ATF3, other genes with putative roles in 
apoptosis were identified as upregulated in GFP+ cells as com-
pared to Control cells (Table 3), including DDB2, PEA15, and 
PPP1R15A. Given the toxicity of lipid-DNA complexes, it is not 
surprising that some apoptotic genes were revealed in the stud-
ies reported here. These results further highlight the need for less 
toxic nonviral delivery systems.
transfection in presence of activators  
of rap1a and HsP70B′
While the major objective of this paper was to examine gene 
expression profiles of transfected cells to identify candidate genes 
for future studies into the molecular mechanisms of gene deliv-
ery, initial transfection experiments, in the presence and absence 
of activators of RAP1A and HSP70B′, further implicate the role 
of these genes in nonviral gene delivery and demonstrate an 
approach to enhancing transfection through priming of the cells 
through molecular factors, without any changes to the cationic 
vector. Most attempts to alter transfection profiles have focused 
on modification of vectors, as opposed to molecular modification 
of cells. While treatment with CPT and heat shock, reported here, 
were likely not specific modulators of RAP1A and HSP70B′ gene 
expression, respectively, these data serve to demonstrate the prin-
ciple of altering endogenous gene expression profiles to enhance 
transfection, and suggest that a cell’s ability to respond to stress 
and adhesion factors may determine the efficacy of gene trans-
fer. Furthermore, given that activation strategies employed here 
were likely not specific to RAP1A or HSP70B′, it might be antici-
pated that molecular approaches to modulate these genes prior 
to DNA delivery could result in an even greater enhancement in 
transfection.
The use of gene delivery in therapeutic applications, includ-
ing gene therapy to treat genetic deficiencies or tissue engineering 
matrices for the treatment of organ loss and failure, has remained 
limited due to challenges with current delivery systems. The lack of 
direct information on the endogenous gene expression profiles and 
intracellular signaling pathways that might be controlling trans-
fection efficiency limits the optimal design of delivery vectors. 
This study is the first to examine the effect of transfection on basal 
cell signaling, to understand the molecular basis for efficient gene 
transfer, and to then in turn use that information to reveal as meth-
ods to prime cells for delivery. Further work is needed to assess the 
effects of different delivery agents, different cell types, earlier time 
points, and molecular interventions on gene expression profiles of 
transfected cells. However, with a greater understanding of endog-
enous gene expression profiles of transfected cells, more efficient 
nonviral delivery schemes capitalizing on endogenous factors can 
be developed to advance therapeutic applications.
MAterIAls And MetHods
Cell culture. HEK 293T cells (ATCC, Manassas, VA), a human embryonic 
epithelial kidney cell line that is widely used for transfection studies, were 
cultured in T-75 flasks in Dulbecco’s modified Eagle’s medium (Gibco/
Invitrogen, Carlsbad, CA) containing 4.5 g/l glucose, supplemented with 
10% fetal bovine serum (Gibco), 2 mmol/l l-glutamine (Gibco), and 100 
units/ml of penicillin (Gibco) and maintained at 37 °C in a humidified 5% 
CO2 atmosphere. For seeding, cells were dissociated with 1 mmol/l EDTA 
and counted using a hemocytometer and trypan blue staining for viable 
cells. Cells were then seeded at a density of 3.4 × 106 cells/flask into T-75 
flasks for transfection, in order to generate enough transfected cells to 
be collected through sorting (see below) for RNA extraction. Additional 
flasks were seeded for control conditions. NIH/3T3 mouse fibroblast cells 
(ATCC) were cultured at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s 
medium (ATCC) supplemented with 10% calf serum (Colorado Serum 
Company, Denver, CO) and 1% penicillin-streptomycin (Gibco). For 
transfection studies in the presence/absence of activators, cells were seeded 
into wells of a 48-well plate (HEK 293T: 22,800 cells/well and NIH/3T3: 
15,000 cells/well) 18 hours prior to activator treatment and subsequent 
transfection.
Transfection for microarray analysis. Plasmid pEGFP-LUC, which 
encodes for both the enhanced green fluorescent protein (EGFP) and 
firefly luciferase protein (LUC) under the direction of a CMV pro-
moter (Clontech, Mountain View, CA), and was used for all transfec-
tion experiments. Plasmids were purified from bacteria culture using 
Qiagen (Valencia, CA) reagents and stored in Tris–EDTA buffer solu-
tion (10 mmol/l Tris, 1 mmol/l EDTA, pH 7.4) at −20 °C. DNA complexes 
were formed with Lipofectamine 2000 (LF2000; Invitrogen), following 
manufacturer’s instructions. Briefly, DNA complexes were formed at a 
DNA:lipid ratio of 1:1.5 (µg of DNA to µl of LF2000) in serum-free, Opti-
MEM media (Invitrogen) by adding transfection reagent diluted in media 
dropwise to DNA in media, mixing by gentle pipetting, and incubating for 
20 minutes. After an 18-hour period to allow HEK 293T cells to adhere 
(seeded into flasks as described above), DNA complexes (11.25 μg DNA 
per flask) were added into the media above the cells. Note, these complex 
conditions (lipid to DNA ratio and DNA amount) were selected based on 
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an exhaustive optimization of transfection conditions in which ratio and 
DNA amounts were compared to (i) transfection efficiency (percentage of 
EGFP-positive cells assayed by fluorescence microscopy using Leica DMI 
3000B, Bannockburn, IL); and (ii) cell viability and morphology (analyzed 
through phase microscopy using Leica DMI 3000B) (Supplementary 
Figure S1). Thus, the above complexation condition represents that with 
the highest transfection efficiency levels (~40%) and lowest cytotoxicity 
(Supplementary Figure S1a,d,e) after 24 hours. Transfection experiments 
for microarray analysis were performed in triplicate on three separate days, 
with some GFP+ and control conditions performed up to six times.
Cell sorting and RNA extraction. Transfected cells (GFP+) were isolated 
from untransfected cells (GFP−) 24 hours after addition of the DNA com-
plexes using flow cytometry (Figure 1). Briefly, cells were removed from 
the flask substrate, counted, and concentrated for subsequent sorting, using 
a B-D FACSVantage SE three-laser, high speed cell sorter in the University 
of Nebraska-Lincoln’s Center for Biotechnology Flow Cytometry Core 
Facility. Cells were sorted based on forward and side scattered gate in the 
presence or absence of fluorescence (Supplementary Figure S2). A sepa-
rate set of flasks of cells that were never exposed to DNA complexes were 
also dissociated, counted, and sorted through flow cytometry. These cells 
are referred to as the Control cells. After obtaining pure populations of 
transfected (GFP+) cells, untransfected (GFP−) cells, and control cells, 
total RNA was extracted using TRIzol reagent following the manufac-
turer’s instructions (Invitrogen) and further purified using Qiagen RNeasy 
column (Qiagen) with a final dilution in DEPC-treated water. All RNA 
samples were quality assessed on a RNA 6000 Nano LabChip using Agilent 
BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA).
Microarray analysis. Fifteen Affymetrix GeneChip Human Genome U133 
Plus 2.0 Arrays (Affymetrix, Santa Clara, CA) were used for the analysis 
of expression of 39,000 human genes in GFP+ (six arrays for six separate 
transfection studies), GFP− (three arrays for triplicate studies on untrans-
fected cells that were exposed to DNA complexes), and Control (six arrays 
for six separate control conditions) HEK 293T cells. All microarray analy-
sis, as described, was performed at University of Nebraska-Lincoln’s Center 
for Biotechnology Genomics and Bioinformatics Core Research Facilities. 
Five to ten micrograms of total RNA was used to synthesize cDNA using 
an Affymetrix One-Cycle cDNA Synthesis Kit according to the manu-
facturer’s instructions. All sample preparations followed prescribed pro-
tocols (Affymetrix Genechip Expression Analysis Technical manual). 
Hybridization was performed at 45 °C overnight on the Affymetrix 
Human Genome Array, stained with streptavidin-phycoerythrin con-
jugate on an Affymetrix Fluidics Station 450, which was followed by 
scanning with the GeneChip Scanner 3000 7G (Affymetrix). Affymetrix 
GeneChip Operating Software (GCOS v1.3) was used for washing, scan-
ning, and basic data analysis. This included calculation of absolute values 
and normalization of the data with respect to internal standards. These 
microarray data were then normalized using methods described by Wu 
et al., 2004.43 Differentially expressed genes between replicates of each 
of the three conditions (GFP+, GFP−, and Control) were determined 
using the linear models for microarrays package in R/Bioconductor, with 
Benjamini-Hochberg adjusted P values.44 Genes that were twofold up- or 
downregulated and had a False Discovery Rate adjusted P value of 0.05 
or less were deemed to be significant. The gene expression data has been 
deposited at the NCBI Gene Expression Omnibus with series number 
GSE20615.
Quantitative real-time PCR. Quantitative real-time PCR was used to con-
firm upregulation of the two genes, RAP1A and HSP70B′. For these studies, 
cells were transfected in T-75 flasks, sorted using flow cytometry and RNA 
extracted, as described above. Total RNA (1 µg)was treated with DNase I 
(Promega, Madison, WI) to remove any genomic DNA and reverse tran-
scribed to cDNA using M-MLV reverse transcriptase (Promega) and ran-
dom primers (Promega). Gene specific primers were designed for RAP1A, 
5′-TGGATACTGCAGGGACAGAGCAAT-3′ (forward), 5′-ACATCTTCC 
GTGTCCTTAACCCGT-3′ (reverse) and HSP70B′, 5′-TGCAAGAGGAA 
AGCCTTAGGGACA-3′ (forward), 5′-ACAGATTTGCTCCAGCTCCCT 
CTT-3′ (reverse). Real-time PCR was performed using Sybr Green and an ABI 
7300 System (Applied Biosystems, Carlsbad, CA). Data was normalized to an 
endo genous control, 18S, using the following primers 5′-CGGCTACCACAT 
CCAAGGAA-3′ (forward), 5′-GCTGGAATTACCGCGGCT-3′ (reverse).
Transfection in presence of gene activators. Transfections were per-
formed in the presence of activators of two identified genes, RAP1A and 
HSP70B′. For either gene, treatments were applied for a period of time, 
then media was removed and replaced with fresh media containing DNA-
lipid complexes formed at 1:1.5 ratio (0.15 µg DNA per well), as described 
above. For RAP1A, 8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′-
cyclic monophosphate sodium salt (8CPT-2Me-cAMP; Tocris Bioscience, 
Ellisville, MO) was added at 20 µmol/l20 for 15 minutes, a concentration 
demonstrated to activate RAP1A without cytotoxicity (data not shown). 
For HSP70B′, the gene was activated by placing cells at 42.5 °C for 1 hour, 
allowing them to recover at 37 °C for 6 hours,21 and then viability was 
monitored before proceeding with transfection. Standard transfection 
in the presence of vehicle alone was used as a control. After 24 hours, 
transfection levels were quantified by measuring the luciferase activity 
using the Luciferase Assay System (Promega), for which cells were lysed 
and assayed for enzymatic activity using a luminometer (Turner Designs, 
Sunnyvale, CA), and luciferase activity (RLUs) was normalized to the total 
protein amount determined with the BCA protein assay (Pierce, Rockford, 
IL). Each transfection experiment was performed in triplicate wells on 
duplicate days. Statistical analysis was performed using Prism software 
(GraphPad Prism 5, LaJolla, CA). Comparative analyses were completed 
using student t-test at a 95% confidence level. Mean values with SEM are 
reported.
suPPleMentArY MAterIAl
Figure S1. Optimization of transfection efficiency.
Figure S2. Sorting of transfected cells.
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